NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that it will be presenting the Company’s development program at 9 am (Israel time) on Wednesday, April 22, 2009 at the Stock Exchange in Tel Aviv, Israel.
